Medical Genetics Test Details
View Custom Req | Tests in Custom Req: 0
|PIK3CA Mutation Analysis - Tumor|
|Test Information:||Indication for Study:
Identification of mutations in exons 9 and 20 of the PIK3CA gene.
Sequence Analysis of exons 9 & 20 of the PIK3CA gene. |
This test can also be performed on FFPE samples (#9035).
Germline mutation analysis is required if novel mutations are detected. Please see detailed requirements under test code (#9037).
PIK3CA is commonly mutated and thereby activated in various human cancers, including colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, breast cancer, cervical cancer, and adenocarcinoma of lung. The most common mutations of PIK3CA are in exon 9 and exon 20. These mutations render tumor cells resistance to some anti-cancer therapies.
This test is designed to detect mutations in exons 9 and 20 of the PIK3CA gene only. The limit of the test is approximately 20 mutated cells in 100 total cells (20%).
Results of this test must always be interpreted in the context of relevant clinical and pathological data, and should not be used alone for a diagnosis of malignancy.
- KRAS, BRAF, PIK3CA, and PTEN Mutations: Implications for Targeted Therapies in Metastatic Colorectal Cancer
- FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy
|Methodology:||Sequence analysis is performed in both forward and reverse directions of exons 9 and 20 of the PIK3CA gene|
|Protein Name:||Phosphatidylinositol 3-Kinase, Catalytic, Alpha|
|Sample & Shipping Information|
|Test Requisition:||Tumor Analysis|
|Specimen Type:||Fresh Frozen Tissue|
|Requirements:||150 mg (0.5-2.0 cm3) Fresh tissue snap frozen at -20°C. Store at -20°C.|
|Shipping Conditions:||Ship on minimum of 10 lbs. of dry ice in an insulated container by overnight courier.
|Turn Around Time:||14 days|
|List Price:||*For Insurance or Institutional Prices, please call.|